Contraindicated. Coadministration of doravirine with a powerful CYP3A inducer may possibly lessen doravirine plasma concentrations and/or effects. Opportunity for loss of virologic reaction and possible resistance to doravirine.pentobarbital will minimize the extent or influence of conivaptan by influencing hepatic/intestinal enzyme CYP3A4 metaboli